Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 03 Feb 2020

The emergence of a novel coronavirus (preliminarily referred to as 2019-nCoV) has taken hold of public attention in the last month. MIMS Doctor speaks to Professor Dale Fisher, a senior consultant at the Division of Infectious Diseases, National University Hospital, Singapore, to get a better picture of the situation and steps being undertaken in Singapore to prevent spread of the virus.

Pearl Toh, 04 Feb 2020
Four months of daily rifampicin is safer than 9 months of daily isoniazid when it comes to treating latent tuberculosis (TB) infection, according to a post hoc safety analysis on pooled data from two randomized studies* — thus rendering the ambitious goal by the WHO to treat 30 million patients possible.
Jairia Dela Cruz, 31 Jan 2020
A week-long course of the centrally acting neurokinin-1 inhibitor aprepitant for treating cough in advanced lung cancer patients is effective and safe, producing significant improvements in cough severity and impact without increasing severe side effects, according to the results of a trial.

Moderate-to-severe COPD exacerbation more common in women than men

30 May 2019

Women with chronic obstructive pulmonary disease (COPD) are at higher risk of exacerbations despite evidence for milder disease at diagnosis compared with men, a study reports.

Researchers used data from the Clinical Practice Research Datalink and linked Hospital Episode Statistics and identified 22,429 COPD patients (48 percent female). Relative to men, women were younger, more likely to be current or nonsmokers, and had lower body mass index, better lung function (as expressed by FEV1% predicted), worse mMRC dyspnoea scale scores and lower blood eosinophils.

Additionally, asthma, anxiety, depression and osteoporosis were more prevalent in women, while cardiovascular comorbidities (myocardial infarction, heart failure and atrial fibrillation) were more common in men.

The risk of first moderate or severe exacerbation was greater by 17 percent in women than in men (hazard ratio [HR], 1.17, 95 percent CI, 1.12–1.23). First exacerbation was also more likely to occur sooner in women (median time, 504 vs 637 days).

The observed differences were more evident among patients in the younger age group (≥40 to <65 years), in GOLD 2016 groups B, C and D, and in those with moderate-to-severe airflow obstruction.

In the first, second and third years of follow-up, the annual rate of moderate or severe exacerbations remained higher in women than men.

The present data underscore the unmet need for appropriate identification and management of women with COPD in clinical practice, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 03 Feb 2020

The emergence of a novel coronavirus (preliminarily referred to as 2019-nCoV) has taken hold of public attention in the last month. MIMS Doctor speaks to Professor Dale Fisher, a senior consultant at the Division of Infectious Diseases, National University Hospital, Singapore, to get a better picture of the situation and steps being undertaken in Singapore to prevent spread of the virus.

Pearl Toh, 04 Feb 2020
Four months of daily rifampicin is safer than 9 months of daily isoniazid when it comes to treating latent tuberculosis (TB) infection, according to a post hoc safety analysis on pooled data from two randomized studies* — thus rendering the ambitious goal by the WHO to treat 30 million patients possible.
Jairia Dela Cruz, 31 Jan 2020
A week-long course of the centrally acting neurokinin-1 inhibitor aprepitant for treating cough in advanced lung cancer patients is effective and safe, producing significant improvements in cough severity and impact without increasing severe side effects, according to the results of a trial.